共有 50 笔近期内部人交易记录记录，涉及 Oramed Pharmaceuticals Inc. (ORMP), 包括 40 笔买入 和 6 笔卖出. 内部人买入总额为 $1.44K 内部人卖出总额为 $1.59M.
近期活跃的重要内部人包括 Kidron Nadav, Kidron Miriam, Hexter Joshua. 内部人交易记录可以揭示公司管理层对股票估值和未来前景的看法.
内部人交易记录 — ORMP
| 日期 |
姓名 |
职位 |
交易类型 |
股数 |
平均价格 |
总价值 |
持股数量 |
| 2026-03-30 |
Kidron Nadav |
President and CEO |
RSU 预扣税 |
44,818 |
$3.31 |
$148.35K |
3,422,243 |
| 2026-03-30 |
Kidron Miriam |
Chief Scientific Officer |
RSU 预扣税 |
435,084 |
$3.31 |
$1.44M |
1,133,138 |
| 2026-03-17 |
Kidron Nadav |
President and CEO |
限制性股票授予 (RSU) |
167,005 |
- |
- |
3,422,243 |
| 2026-03-17 |
Kidron Miriam |
Chief Scientific Officer |
限制性股票授予 (RSU) |
119,558 |
- |
- |
1,568,222 |
| 2026-03-17 |
Hexter Joshua |
COO & Cbo |
限制性股票授予 (RSU) |
95,889 |
- |
- |
1,160,384 |
| 2026-03-17 |
Gabay Avraham |
Chief Financial Officer |
限制性股票授予 (RSU) |
95,889 |
- |
- |
745,145 |
| 2026-03-12 |
Kidron Nadav |
President and CEO |
赠与（送出） |
100,000 |
- |
- |
3,255,238 |
| 2026-01-22 |
Kidron Nadav |
President and CEO |
期权行权（卖出） |
109,000 |
- |
- |
- |
| 2026-01-22 |
Kidron Miriam |
Chief Scientific Officer |
期权行权（卖出） |
19,000 |
- |
- |
- |
| 2026-01-22 |
Hexter Joshua |
COO & Cbo |
期权行权（卖出） |
19,000 |
- |
- |
- |
| 2026-01-22 |
Gabay Avraham |
Chief Financial Officer |
期权行权（卖出） |
19,000 |
- |
- |
- |
| 2026-01-14 |
Kidron Miriam |
Chief Scientific Officer |
赠与（送出） |
86,166 |
- |
- |
1,343,498 |
| 2025-12-31 |
Gabay Avraham |
Chief Financial Officer |
限制性股票授予 (RSU) |
19,000 |
- |
- |
19,000 |
| 2025-12-31 |
Aghion Daniel |
Director |
限制性股票授予 (RSU) |
30,000 |
$0.01 |
$360.00 |
107,191 |
| 2025-12-31 |
Kidron Nadav |
President and CEO |
限制性股票授予 (RSU) |
109,000 |
- |
- |
109,000 |
| 2025-12-31 |
Kidron Miriam |
Chief Scientific Officer |
限制性股票授予 (RSU) |
19,000 |
- |
- |
19,000 |
| 2025-12-31 |
Hexter Joshua |
COO & Cbo |
限制性股票授予 (RSU) |
19,000 |
- |
- |
19,000 |
| 2025-12-31 |
Mayer Arie |
Director |
限制性股票授予 (RSU) |
30,000 |
$0.01 |
$360.00 |
163,109 |
| 2025-12-31 |
Shapiro Benjamin |
Director |
限制性股票授予 (RSU) |
30,000 |
$0.01 |
$360.00 |
119,720 |
| 2025-12-31 |
Reznick Yehuda |
Director |
限制性股票授予 (RSU) |
30,000 |
$0.01 |
$360.00 |
98,930 |
| 2025-06-05 |
Sank Leonard |
Director |
限制性股票授予 (RSU) |
30,000 |
- |
- |
128,021 |
| 2025-06-05 |
Mayer Arie |
Director |
限制性股票授予 (RSU) |
30,000 |
- |
- |
126,134 |
| 2025-06-05 |
Shapiro Benjamin |
Director |
限制性股票授予 (RSU) |
30,000 |
- |
- |
85,070 |
| 2025-06-05 |
Aghion Daniel |
Director |
限制性股票授予 (RSU) |
30,000 |
- |
- |
68,820 |
| 2025-06-05 |
Reznick Yehuda |
Director |
限制性股票授予 (RSU) |
30,000 |
- |
- |
60,560 |
| 2025-02-11 |
Kidron Nadav |
President and CEO |
限制性股票授予 (RSU) |
141,000 |
- |
- |
2,400,598 |
| 2025-02-11 |
Kidron Miriam |
Chief Scientific Officer |
限制性股票授予 (RSU) |
74,000 |
- |
- |
1,074,666 |
| 2025-02-11 |
Hexter Joshua |
COO & Cbo |
限制性股票授予 (RSU) |
45,000 |
- |
- |
751,333 |
| 2025-02-11 |
Gabay Avraham |
Chief Financial Officer |
限制性股票授予 (RSU) |
34,000 |
- |
- |
392,040 |
| 2025-01-02 |
Kidron Nadav |
President and CEO |
限制性股票授予 (RSU) |
433,500 |
- |
- |
2,259,598 |
| 2025-01-02 |
Kidron Miriam |
Chief Scientific Officer |
限制性股票授予 (RSU) |
207,000 |
- |
- |
1,000,666 |
| 2025-01-02 |
Hexter Joshua |
COO & Cbo |
限制性股票授予 (RSU) |
194,500 |
- |
- |
706,333 |
| 2025-01-02 |
Gabay Avraham |
Chief Financial Officer |
限制性股票授予 (RSU) |
188,000 |
- |
- |
358,040 |
| 2024-11-07 |
Kidron Nadav |
President and CEO |
限制性股票授予 (RSU) |
45,000 |
- |
- |
1,826,098 |
| 2024-11-07 |
Kidron Miriam |
Chief Scientific Officer |
限制性股票授予 (RSU) |
30,000 |
- |
- |
793,666 |
| 2024-11-07 |
Hexter Joshua |
COO & Cbo |
限制性股票授予 (RSU) |
30,000 |
- |
- |
511,833 |
| 2024-11-07 |
Gabay Avraham |
Chief Financial Officer |
限制性股票授予 (RSU) |
30,000 |
- |
- |
170,040 |
| 2024-06-21 |
Gabay Avraham |
Chief Financial Officer |
限制性股票授予 (RSU) |
140,040 |
- |
- |
- |
| 2024-06-18 |
Gabay Avraham |
Officer |
未知 |
- |
- |
- |
- |
| 2024-06-06 |
Reznick Yehuda |
Director |
限制性股票授予 (RSU) |
760 |
- |
- |
30,560 |
| 2024-04-17 |
Reznick Yehuda |
Director |
限制性股票授予 (RSU) |
29,800 |
- |
- |
29,800 |
| 2024-04-01 |
Reznick Yehuda |
Director |
未知 |
- |
- |
- |
- |
| 2024-01-30 |
Aghion Daniel |
Director |
限制性股票授予 (RSU) |
3,750 |
- |
- |
38,820 |
| 2024-01-04 |
Kidron Nadav |
President and CEO |
限制性股票授予 (RSU) |
329,000 |
- |
- |
1,781,098 |
| 2024-01-04 |
Kidron Miriam |
Chief Scientific Officer |
限制性股票授予 (RSU) |
295,500 |
- |
- |
763,666 |
| 2024-01-04 |
Sank Leonard |
Director |
限制性股票授予 (RSU) |
30,000 |
- |
- |
88,696 |
| 2024-01-04 |
Hexter Joshua |
COO & Cbo |
限制性股票授予 (RSU) |
180,500 |
- |
- |
481,833 |
| 2024-01-04 |
Mayer Arie |
Director |
限制性股票授予 (RSU) |
30,000 |
- |
- |
86,809 |
| 2024-01-04 |
Silberman David |
Chief Financial Officer |
限制性股票授予 (RSU) |
136,500 |
- |
- |
366,500 |
| 2024-01-04 |
Rozov Yadin |
Director |
限制性股票授予 (RSU) |
30,000 |
- |
- |
146,500 |
■ 知情交易 — 公开市场买卖（最具参考价值）
■ 非知情买入 — 奖励、期权行权、转换
■ 非知情卖出 — 税务代扣、归属出售
■ 中性 — 礼赠、信托、到期
